Transplantation of autologous, genetically modified HSPCs that express an EGFA-GPA chimeric protein, could therefore be a practical and one-shot preventative treatment for cardiovascular disease and obesity in humans, especially those with a genetic predisposition to high cholesterol levels. This evidence concerns the gene GYPA and cardiovascular disorder.